The Periodontal Therapeutics Market Size was valued at USD 843.6 Mn in 2023 and is predicted to reach USD 1,497.4 Mn by 2031 at a 7.6% CAGR during the forecast period for 2024-2031.
Periodontal disease encompasses a wide range of inflammatory conditions affecting the tissues surrounding the teeth. It primarily includes gingivitis (mild inflammation of the gums) and periodontitis (severe inflammation that can lead to tooth loss). Gingivitis is reversible with the help of proper care, but if it is left untreated, it can lead to periodontitis, which is more challenging to manage. The growth of the market is due to the growing prevalence of periodontal diseases. Increasing awareness about oral health, the rising geriatric population, and technological advancements in dentistry are further propelling the growth of the market. Also, the recommendation of drugs like antibiotics is rising in the same field. It is quite advantageous for the growth of the periodontal market.
The COVID-19 pandemic has significantly impacted the periodontal therapeutics market. Dental clinics and periodontal practices faced temporary closures and reduced patient visits due to lockdowns and social distancing measures. It led to a decline in the demand for periodontal treatments. However, the pandemic also heightened awareness of the importance of oral health, potentially driving future market growth. Telehealth services and remote consultations emerged as alternative approaches, aiding in patient management during the crisis. As restrictions ease and normalcy returns, the market is expected to recover, with an increased focus on infection control and preventive care.
Competitive Landscape
Some of the Major Key Players in the Periodontal Therapeutics Market are
- Pfizer Inc.
- Lupin Ltd
- Teva Pharmaceuticals USA, Inc.
- Sun Pharmaceutical Industries Ltd.
- Tokyo Chemical Industry Co., Ltd.
- Bausch Health Companies Inc.
- USAntibiotics
- Melinta Therapeutics LLC
- Cipla, Inc.
- Chartwell Pharmaceuticals LLC.
- Other Prominent Players
Market Segmentation:
The periodontal therapeutics market is segmented on the basis of disease, drug type, and distributional channel. By Disease type, the market segments include gingivitis, chronic periodontal disease, aggressive periodontal disease, and others. On the basis of drug type, the segments are doxycycline, minocycline, chlorhexidine, metronidazole, and others. By distribution channel, the segmentation includes hospital pharmacies, retail pharmacies, and online channels.
Based on Disease Type, the Gingivitis Segment is Considered a Major Contributor to the Periodontal Therapeutics Market.
The gingivitis segment of the periodontal therapeutics market is growing due to increased awareness of oral health and the prevalence of gum diseases. Gingivitis, an early stage of periodontal disease, is the inflammation of the gums as well as can lead to many severe conditions if untreated. The market includes various treatment options, such as antiseptic mouthwashes, antibiotics, and professional dental cleanings. Innovations in dental care products and a rising focus on preventive healthcare are driving market growth. Additionally, increased dental visits and advancements in diagnostic tools contribute to the expansion of this segment within the periodontal therapeutics market.
The Doxycycline Segment Witnessed Growth at a Rapid Rate.
The doxycycline segment of the periodontal therapeutics market is a significant component in treating periodontal diseases. Doxycycline, a type of antibiotic, is commonly used in the form of gel or subgingival fibers to target specific bacteria causing periodontitis. It works by reducing inflammation and inhibiting bacterial growth in the periodontal pockets. The segment is seen to grow due to the effectiveness of doxycycline in managing periodontal conditions, its ease of application, and favorable patient outcomes. With increasing emphasis on oral health and advancements in periodontal treatments, the doxycycline segment plays a crucial role in the periodontal therapeutics market.
In the Region, the North American Periodontal Therapeutics Market Holds a Significant Revenue Share.
North America's periodontal therapeutics market dominates the market. It has been initiated to increase awareness about oral health—the rise in effective procedures for the treatment and diagnosis of periodontal diseases. Hence, the sales of periodontal treatment products, including both drugs and devices, in the region are quite high. Asia Pacific is to be seen to grow at a rapid rate in the global periodontal therapeutics market due to growing concerns about rapid industrialization, government initiatives, and increasing funding in various industries.
Recent Developments:
- In February 2020, AMD Lasers announced the development of the Monet™ laser curing light, the first handheld laser in curing light for dental materials.
- In 2019, OraVu, which is a dental technology company dealing in dental endoscopy solutions, launched a complete micro-endoscope system called DeVA-1® Dental Vision Assistant.
Periodontal Therapeutics Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 843.6 Mn |
|
Revenue Forecast In 2031 |
USD 1,497.4 Mn |
|
Growth Rate CAGR |
CAGR of 7.6% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Disease, By Drug Type, By Distribution Channel and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Pfizer Inc., Lupin Ltd., Teva Pharmaceuticals USA, Inc., Sun Pharmaceutical Industries Ltd., Tokyo Chemical Industry Co., Ltd., Bausch Health Companies Inc., USAntibiotics, Melinta Therapeutics LLC, Cipla, Inc., Chartwell Pharmaceuticals LLC, and other prominent players. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
